New developments in biomarkers for epithelial ovarian cancer

November 29, 2007

AMSTERDAM, November 29th 2007 - With the genomic revolution radical improvement has been made in methods of detection of ovarian cancer. This is of the utmost importance, since the chances of successful treatment are strongly enhanced with early detection. In a special issue of Disease Markers, published by IOS Press, eleven articles explore new developments in the identification and understanding of biomarkers for epithelial ovarian cancer.

"Many of these biomarkers may serve not only as markers of clinical and biology interest but also as potential therapeutic and imaging targets which could significantly improve the survival of patients with this disease," states Prof. Michael J. Birrer (National Cancer Institute, Center for Cancer Research, Cell and Cancer Biology Department, MD, USA).

Discussed in the issue are new hypotheses on the molecular development of ovarian cancer, SP markers of risk, biomarkers that are specific for the different histological subtypes, and new biomarkers and approaches for the early detection of ovarian cancer. Furthermore, new molecular technologies have allowed for the analysis and characterization of specific cellular components of ovarian tumors identifying biomarkers of tumor associated immune and endothelial cells.
The articles appear in a special, single-topic issue of Disease Markers, Volume 23:5,6 (November 2007), published by IOS Press.

©2007 IOS Press. All rights reserved. Unauthorized use prohibited.

"Biomarkers in Ovarian Disease" is a special issue of the IOS Press journal Disease Markers (Volume 23, Number 5,6 (2007)), guest edited by Michael J. Birrer.

Table of Contents

Preface/ M.J. Birrer

Non-genomic biomarkers of risk in ovarian cancer/ S.P. Pinheiro and D.W. Cramer

Etiology and pathogenesis of epithelial ovarian cancer/ S.C. Mok, J. Kwong, W.R. Welch, G. Samimi, L. Ozbun, T. Bonome, M.J. Birrer, R.S. Berkowitz and K-K. Wong

The continuum of serous tumors of low malignant potential and low-grade serous carcinomas of the ovary/ K-K. Wong and D. Gershenson

Biomarkers of mucinous tumors of the ovary/ G. Samimi, L. Ozbun, M.E. Johnson, S.C. Mok and M.J. Birrer

Early detection of ovarian cancer/ D. Badgwell and R.C. Bast Jr.

Proteomics as a tool for biomarker discovery/ E.C. Kohn, N. Azad, C. Annunziata, A.S. Dhamoon and G. Whiteley

Markers of angiogenesis in ovarian cancer/ W.M. Merritt and A.K. Sood

Cell cycle and related protein/ J. Farley, L. Ozbun, G. Samimi and M.J. Birrer

Immune prognostic factors in ovarian cancer: Lessons from translational research/ P.A. Gimotty, L. Zhang, I. Alagkiozidis, M. Cadungog, S. Adams, C. Chu, D. Katsaros and G. Coukos

Claudin proteins in ovarian cancer/ P.J. Morin

Utilizing virtual microscopy for quality control review/ N.C. Ramirez, T.J. Barr and D.M. Billiter

About Disease Markers

Established in 1984, Disease Markers (ISSN: 0278-0240, Editor-in-Chief: Sudhir Srivastava PhD, MPH, publishes original research findings and review articles on the subject of the identification of markers associated with the disease processes whether or not they are an integral part of the pathological lesion.

About IOS Press

IOS Press (, celebrating its 20th anniversary, publishes some 85 international journals and approximately 100 book titles a year, ranging from computer sciences and mathematics to medicine and the natural sciences. Commencing its publishing activities in 1987, IOS Press serves a variety of scientific and medical communities in all parts of the world. IOS Press is a rapidly-growing publishing company that embraces new technologies for the dissemination of information. All journals are available online and an online book platform was launched in the first half of 2006. Following its founding, IOS Press established several co-publishing initiatives. Its most recent expansion is the acquisition of Delft University Press at the end of 2005. IOS Press also maintains offices in the Washington, DC area, Berlin and a co-publishing relationship with Ohmsha, Ltd (Tokyo).

IOS Press

Related Ovarian Cancer Articles from Brightsurf:

Ovarian cancer cells cooperate to metastasize
In a study on human ovarian cancer cells in mice, Harvard Medical School researchers discovered a transient, cooperative interaction between cell subpopulations that allows otherwise nonmetastatic tumor cells to become aggressive and spread.

Photodynamic therapy used to treat ovarian cancer
Photodynamic therapy (PDT) is one of the most promising methods of treating localized tumors.

Studying the development of ovarian cancer with organoids
Researchers from the group of Hans Clevers at the Hubrecht Institute have modeled the development and progression of high-grade serous ovarian cancer in mini-versions, or organoids, of the female reproductive organs of the mouse.

New class of drugs could treat ovarian cancer
A team of researchers across the University of Manchester have shown that a new class of drugs are able to stop ovarian cancer cells growing.

How to catch ovarian cancer earlier
Ovarian cancer is often diagnosed too late for effective treatment.

New compound could help treat ovarian cancer
Scientists from the University of Sheffield have discovered a compound that could be more effective in treating certain cancers than standard chemotherapy.

Epigenetic markers of ovarian cancer
Insilico Medicine and its collaborators from Johns Hopkins and Insilico Medicine, used an integrated approach by coupling identification of genome-wide expression patterns in multiple cohorts of primary ovarian cancer samples and normal ovarian surface epithelium with innovative computational analysis of gene expression data, leading to the discovery of novel cancer-specific epigenetically silenced genes.

Ovarian cancer statistics, 2018
A new report from the American Cancer Society provides an overview of ovarian cancer occurrence and mortality data.

Ovarian cancer drug shows promise in pancreatic cancer patients with BRCA mutation
A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.

TGen-led study finds potent anti-cancer drug effect in rare ovarian cancer
An anti-cancer drug used to fight leukemia shows promise against a rare and aggressive type of ovarian cancer -- small cell carcinoma of the ovary hypercalcemic type (SCCOHT) -- which strikes young women and girls, according to a study led by the TGen.

Read More: Ovarian Cancer News and Ovarian Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to